Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01567254
Other study ID # 54/11
Secondary ID
Status Completed
Phase N/A
First received February 1, 2012
Last updated January 1, 2015
Start date April 2012
Est. completion date May 2012

Study information

Verified date January 2015
Source Assaf-Harofeh Medical Center
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Background: Pediatric patients with type 1 diabetes mellitus are known to be a challenging group for achieving recommended glycemic control. Coping with the demands of self-managing IDDM in children and adolescents can be a formidable task, requiring a healthy and balanced diet, monitoring and regular insulin injections. Most patients are non-compliant to the treatment. A number of controlled studies have examined the efficiency of psychosocial interventions for improving compliance and glycemic control among diabetic youth. None has examined the effectiveness of guided imagery in treatment of type 1 diabetes mellitus.

Primary Objective: To asses simultaneously the effect of listening to auditory guided imagery and blood glucose variability, compared to variability in blood glucose while listening to songs.

Secondary Objective To assess the effect of routine auditory guided imagery to glycemic control and quality of life in children with type 1 diabetes mellitus, compared to listening listening to songs.

Methods:

Subjects: 14 youth ages 7-16 years with type 1 diabetes mellitus , for at least 6 months, and not during the honey moon period will be recruited, and will be blindly randomized to receive intervention (auditory guided imagery group) or control (regular auditory music).

Protocol:

Design: A randomized Controlled Blinded Study Intervention: 14 randomly numbered CD's will be prepared at study initiation, half containing auditory guided imagery and half containing music.

Study protocol: After an initial check up, including HbA1C levels, and explanation of study procedures the participants will be given either the intervention or the control CD, to be used twice a day for five days. During this period continuous glucose monitoring will be performed. On days one and five the procedure will take place while the participants are connected to biofeedback. QOL questionnaires will be completed at the beginning of day one, or before.

In the second part of the study the children will use the intervention / control CD at home twice a week for 12 weeks. At the end of the study period they will again be evaluated, including HbA1C, and all subjects will again complete QOL questionnaires


Description:

14 participants will be assigned research numbers in a consecutive recruitment order.(01-14).

14 auditory disks will be prepared ahead of study initiation, 7 with the guided imagery program and 7 with regular songs.

All will look similar from the outside. The disks will be numbered 01-14. Disks numbering will be performed by an investigator who is not part of treatment team, without knowing which disk contains which content. So that the team and participants are blinded to the disk content at initiation.

Children and parents will be aware of the type of auditory disk after initial auscultation at visit number 1.

The team will continue to be blinded to type of disk until end of study. 3. All participants will be aware at study initiation that they may receive the auditory guided imagery disk or a regular songs / story auditory disk.

4. Visit no. 1:

1. Will be arranged on date of their regular clinic visit

2. Guidance to disk usage

3. Biofeedback for autonomic parameters assessment

4. Participants will be connected to the continuous glucose monitoring system (A system which the patient is blinded to glucose readings).

5. Participants and parents will fill QOL questionnaire [The Diabetes Treatment Satisfaction Questionnaire (DTSQ) by Bradley C. et Al (16)], if not filled before.

6. Participants will listen to disk for the first time in clinic, alone in a room with the parent

7. At this stage participants will be aware of the group they are in (treatment vs. control), but team is still unaware.

8. Participants will be able to come with brothers and parents and recreational activity will be available at site for all for entertainment 5. Visit no. 2-5: 6. Participants will listen to disk twice a day for the next four days alone in a room in our clinic. They will be able to come with brothers and parents, and recreational activity will be available at site for all for entertainment.

7. 5th day visit:

a. Participants will listen to disk for the last times in clinic, alone in a room.

b. Participants will be disconnected from CGMS c. Biofeedback for autonomic parameters assessment 8. Participants will listen to disk at least twice a week, for additional 11 weeks, at their choice of time and day, and will record the specific time of listening on study chart 9. Visit no. 6:

1. Will be arranged on date of their regular clinic visit (12-14 weeks after visit no. 1)

2. Biofeedback for autonomic parameters assessment

3. Participants and parents will fill QOL questionnaires (The Diabetes Treatment Satisfaction Questionnaire (DTSQ) by Bradley C. et Al (16)

4. End of study 10. Data will be collected from charts from dates of visit no. 1 and visit no. 3 regarding: weight, height, BMI, 14 days average blood glucose levels, HbA1c.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Both
Age group 7 Years to 16 Years
Eligibility Inclusion Criteria:

- Type 1 diabetes mellitus for longer than 6 months

- Insulin requirements of more than 0.4 units/kg/day for at least 3 months

- Age 7-16 years

- Agreement of parents or guardian to participate in the study

- Agreement and wiliness of child to participate in the study

Exclusion Criteria:

- Children with cognitive impairment which prevents them from using guided imagery

- Unable to understand Hebrew

- Hearing defect

- Attention deficit disorder

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
guided imaginary
Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
music ONLY
music. It will be equal in length to the auditory guided imagery disk

Locations

Country Name City State
Israel Assaf Haroffeh Medical center Zerifin

Sponsors (1)

Lead Sponsor Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood glucose values before and after listening to the recording. Blood glucose variability of teenagers before and after listening to auditory guided imagery, compared to the blood glucose variability of teenagers before and after listening to music. The blood glucose values will be measured by continuous glucose monitoring system (CGMS). 1 week No
Secondary The delta of HA1C between before and after three months of periodic listening to auditory guided imagery, compared to listening to music. Average of deltas of HA1C between before and after three months of peridic listening to auditory guided imagery, compared to listening to music. 3 months No
See also
  Status Clinical Trial Phase
Recruiting NCT01322789 - Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients Phase 1/Phase 2
Completed NCT00035750 - Risk Factors for Atherogenesis in Type 1 Diabetes N/A
Completed NCT00005754 - Coronary Artery Calcification in Type 1 Diabetes N/A
Completed NCT00005474 - Markers and Mechanisms of Macrovascular Disease in IDDM N/A
Completed NCT01236365 - Statins in Children With Type 1 Diabetes and Hypercholesterolemia Phase 3
Completed NCT01216618 - Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies Phase 3
Completed NCT00071409 - Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes Phase 2
Completed NCT00069537 - Continuous Glucose Monitors for Children With Diabetes Mellitus Phase 4
Completed NCT05168657 - Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth N/A
Withdrawn NCT00297635 - Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy Phase 2
Completed NCT00184821 - Ischemic Injury and Ischemic Preconditioning in Diabetes N/A
Completed NCT00073255 - Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT00690066 - PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM) Phase 2
Active, not recruiting NCT04078308 - Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients Phase 1/Phase 2
Completed NCT00069628 - Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer Phase 4
Completed NCT00044395 - Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes Phase 3
Completed NCT00044408 - Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes Phase 3
Completed NCT00069615 - Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children Phase 4
Completed NCT00005539 - Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes N/A
Completed NCT04689685 - The RADAR Study - Wearable-Based Dysglycemia Detection and Warning in Diabetes